#Brazil #Sanofi #BioManguinhos #deal
He Institute of Technology in Immunobiologicals (Bio-Manguinhos), belonging to the Oswaldo Cruz Foundation (Fiocruz) from Brazilsigned a agreement with the French Sanofi. Under this memorandum of understanding, Sanofi will transfer the technology for the national production of the hexavalent acellular vaccine.
The vaccination it is on the agenda in Latin America. And within the framework of Brazil-France Economic Forum, Bio-Manguinhos y Sanofi signed an agreement to deepen your collaboration in the vaccine production. This way, Sanofi will transfer the technology y Bio-Manguinhos will go on to produce and supply the hexavalent acellular vaccine al National Immunization Program (PNI). See Statement.
The vaccine offers protection against six diseases which can be serious: diphtheriatetanus, whooping coughdiseases caused by bacteria Haemophilus influenzae tipo Bhepatitis B y polio. Ver Linkedin
Both parties maintain a permanent collaboration for transfer technology for the Inactivated Polio Vaccine (VIP), available in the Unified Health System (SUS) since August 2012. And, furthermore, The agreement also establishes mutual interest in explore new collaborations for the innovation in the field of vaccines.
As reported Bio-Manguinhoswhose director is Mauricio Zumalas combined vaccines son «an important pillar for advance vaccination coverage«, since they allow simplify the calendarhelping increase coverage rates against infectious diseases. In turn, this also represents profits in the cold chain y in logisticsand optimize the work of health professionals at the endproviding greater savings for SUS.
